Brief: Xbiotech Announces Plan To Launch Randomized Phase 2B Study Of Bermekimab In Hidradenitis Suppurativa
23/05/2019 14:13
May 23 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES PLAN TO LAUNCH RANDOMIZED PHASE 2B
STUDY OF
BERMEKIMAB IN HIDRADENITIS SUPPURATIVA
* XBIOTECH INC - COMPANY EXPECTS FIRST PATIENT TO BE
ENROLLED
DURING Q3 OF 2019.
Source text for Eikon: ID:nGNE1b8BcV
Further company coverage: XBIT.O
((Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke